GlaxoSmithKline (NYSE: GSK) is among the bidders for India-based Paras Pharma, according to the Business Standard in Mumbai, India.
Paras, which makes over-the-counter drugs, is expected to draw bids of about $1 billion. However, initial bidding was lower at between $600 million and $700 million, the newspaper said.
GSK operates its U.S. headquarters in Research Triangle Park.
Other bidders reported include Novartis, Sanofi-Aventis and Johnson & Johnson.
For more details,
Get the latest news alerts: at Twitter.
